Publication date: Aug 10, 2019
Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and after completion of therapy in adults with advanced melanoma.
In this phase 2, single-arm, open-label study, T-VEC was administered into injectable lesions initially at 10 plaque-forming units (PFU)/mL, 10 PFU/mL 21 days later, and 10 PFU/mL every 14 (+/-3) days thereafter. Injected lesions were covered with occlusive dressings for ≥1 week. Blood, urine, and swabs from exterior of occlusive dressings, surface of injected lesions, oral mucosa, anogenital area, and suspected herpetic lesions were collected throughout the study. Detectable T-VEC DNA was determined for each sample type; infectivity was determined for all swabs with detectable T-VEC DNA.
Sixty patients received ≥1 dose of T-VEC. During cycles 1-4, T-VEC DNA was detected in blood (98.3% of patients, 36.7% of samples), urine (31.7% of patients, 3.0% of samples) and swabs from injected lesions (100% of patients, 57.6% of samples), exterior of dressings (80% of patients,19.5% of samples), oral mucosa (8.3% of patients, 2.5% of samples), and anogenital area (8.0% of patients, 1.1% of samples). During the safety follow-up period, T-VEC DNA was only detected on swabs from injected lesions (14% of patients, 5.8% of samples). T-VEC DNA was detected in 4/37 swabs (3/19 patients) of suspected herpetic lesions. Among all samples, only those from the surface of injected lesions tested positive for infectivity (8/740 [1.1%]). Three close contacts reported signs and symptoms of suspected herpetic origin; however, no lesions had detectable T-VEC DNA.
Using current guidelines, T-VEC can be administered safely to patients with advanced melanoma and is unlikely to be transmitted to close contacts with appropriate use of occlusive dressings. FUND: This study was funded by Amgen Inc.: ClinicalTrials.gov, NCT02014441.
Andtbacka, R.H.I., Amatruda, T., Nemunaitis, J., Zager, J.S., Walker, J., Chesney, J.A., Liu, K., Hsu, C.P., Pickett, C.A., and Mehnert, J.M. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. 23750. 2019 EBioMedicine.
- Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.